Ετικέτες

Τετάρτη 17 Νοεμβρίου 2021

The risk factors for Graves' ophthalmopathy

xlomafota13 shared this article with you from Inoreader

pubmed-meta-image.png

Graefes Arch Clin Exp Ophthalmol. 2021 Nov 17. doi: 10.1007/s00417-021-05456-x. Online ahead of print.

ABSTRACT

PURPOSE: This review aimed to provide an overview of current research into the risk factors for Graves' ophthalmopathy (GO).

METHODS: To find information about the risk factors for GO, the research database PubMed was searched and relevant articles were obtained to extract information about risk factors.

RESULTS: Smoking has been widely accepted as an importan t risk factor and cigarette smoking cessation has been shown to improve the outcome and decrease the onset of GO. Radioactive iodine on the thyroid may induce hyperthyroidism and increase the occurrence of GO. Selenium deficiency is a risk factor for GO and the supplementation of selenium has been an adjuvant therapy. Decreasing stressful life events (SLE) may help improve GO. Imbalance in intestinal flora is essential to GO, with Yersinia enterocolitica and Escherichia coli both increased in the digestive tract of the individual with GO. In addition, controlling serum cholesterol may help improve GO since adipogenesis is an important pathological change in its pathogenesis. Considering the correlation between Graves' disease and GO, maintaining normal thyroid function hormone level is the first-line therapeutic strategy to prevent progression of GO. An increase in antibodies such as TSHR and IGF-1R is the main predictor of GO. Besides, gender and gene polymorphism are also risk fac tors towards GO.

CONCLUSIONS: Risk factors for GO arise from five sources: physical and chemical environment, social-psychological environment, biological environment, the human organism, and genetic codes. Risk factors within these categories may interact with each other and their mechanisms in promoting the development of GO are complex. Research into risk factors for GO may promote emerging fields related to GO such as control of autoantibodies and intestinal microbiota.

PMID:34787691 | DOI:10.1007/s00417-021-05456-x

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου